Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · IEX Real-Time Price · USD
4.180
-0.090 (-2.11%)
At close: Mar 28, 2024, 4:00 PM
4.260
+0.080 (1.91%)
After-hours: Mar 28, 2024, 6:16 PM EDT
Century Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for IPSC stock have an average target of 14.17, with a low estimate of 5.00 and a high estimate of 24. The average target predicts an increase of 239.00% from the current stock price of 4.18.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IPSC stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 3 | 4 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +474.16% | Mar 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +211.00% | Mar 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +211.00% | Dec 7, 2023 |
JP Morgan | JP Morgan | Buy → Hold Downgrades $28 → $5 | Buy → Hold | Downgrades | $28 → $5 | +19.62% | Aug 28, 2023 |
Piper Sandler | Piper Sandler | Buy Maintains $14 → $10 | Buy | Maintains | $14 → $10 | +139.23% | Aug 10, 2023 |
Financial Forecast
Revenue This Year
7.63M
from 2.24M
Increased by 241.48%
Revenue Next Year
54.15M
from 7.63M
Increased by 609.45%
EPS This Year
-2.25
from -2.30
EPS Next Year
-1.39
from -2.25
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 32.5M | 105.0M | 52.5M | 52.5M | 118.7M |
Avg | 7.6M | 54.1M | 51.0M | 51.0M | 115.3M |
Low | n/a | 14.7M | 49.0M | 49.0M | 110.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1,355.2% | 1,275.8% | -3.0% | 2.9% | 132.6% |
Avg | 241.5% | 609.4% | -5.8% | - | 126.0% |
Low | - | 92.6% | -9.5% | -3.9% | 117.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.41 | -0.83 | -2.01 | -2.07 | -1.34 |
Avg | -2.25 | -1.39 | -1.95 | -2.01 | -1.31 |
Low | -2.70 | -1.83 | -1.87 | -1.93 | -1.25 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.